Alnylam Pharma reports positive ALN-TTR02 clinical data
:00AM Alnylam Pharma reports positive ALN-TTR02 clinical data, with robust knockdown of serum transthyretin of up to 94% after single dose (ALNY) 12.52 : Co announces the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis. Results from this study show that administration of ALN-TTR02 leads to robust knockdown of serum TTR protein levels of up to 94%; the overall results were highly significant. Suppression of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, durable, and specific after just a single dose. Co recently reported that it has initiated a Phase II study of ALN-TTR02 in patients with ATTR and has guided that its goal is to start a pivotal trial in 2013.